Opportunity Information: Apply for PA 13 265
Apply for PA 13 265
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Synergizing Omic and Symptom Science (R15)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research.
- This funding opportunity was created on Jul 9, 2013 and posted on Jul 9, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Synergizing Omic and Symptom Science (R15) funding opportunity (PA 13-265) is an NIH grant announcement designed to support research that deliberately connects what is happening at the molecular and biological level with what patients actually experience and report. The core idea is to integrate "omics" style data (for example, information reflecting genetic, genomic, proteomic, metabolomic, inflammatory, or other biological process measurements) with patient-reported outcomes such as symptoms, functional status, and health-related quality of life. In practice, the opportunity is aimed at projects that move beyond studying biology or symptoms in isolation and instead combine these streams of evidence to better understand why symptoms occur, vary between people, cluster together, or change over time, and how those symptom patterns relate to underlying biological mechanisms.
This announcement uses the NIH R15 mechanism, which is the Academic Research Enhancement Award (AREA). R15 grants are generally intended to strengthen the research environment in educational institutions and to support meritorious research while exposing students to research experiences. The funding instrument type is a grant, and the activity category is listed under education and health, with the CFDA number 93.361 (Nursing Research), indicating alignment with health research priorities that include, but are not limited to, nursing and symptom science. The announcement specifically emphasizes bringing together diverse data types, which signals that strong proposals would typically include thoughtful plans for collecting, harmonizing, and analyzing both biological measures and patient-reported measures rather than treating one as an optional add-on.
In terms of practical funding parameters, the award ceiling is listed as $300,000, and there is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of receiving the award. The opportunity was posted on July 9, 2013, with an original and final closing date of September 7, 2016, and it was archived on October 8, 2016. While that means this specific announcement is no longer open, the summary still matters for understanding the type of research NIH was seeking under this program and for identifying similar, current opportunities with comparable aims.
Eligibility is centered on institutions of higher education. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education. The announcement also calls out additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs). Foreign institutions (non-U.S. entities) are explicitly not eligible to apply, and non-domestic components of U.S. organizations are also not eligible. However, foreign components, as defined by the NIH Grants Policy Statement, are allowed, which typically means a U.S. applicant organization can include certain well-justified activities conducted in a foreign setting when they are necessary for the project and meet NIH policy requirements.
The sponsoring agency is the National Institutes of Health. The full announcement was hosted on the NIH grants site (the Additional Information link points to the archived FOA page). For technical issues accessing the announcement or linking problems, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, which is a support contact rather than a scientific or programmatic contact.
Overall, the opportunity is best understood as an effort to push symptom science toward more mechanistic, integrative models by pairing patient-centered outcomes with molecular-level data. Projects responsive to this kind of announcement typically emphasize multidisciplinary collaboration (for example, combining clinical symptom expertise, biostatistics, and bioinformatics), rigorous measurement of patient-reported outcomes, careful selection of biological markers or omics platforms, and analysis strategies capable of linking multilevel biological signals to symptom variability and quality-of-life impacts.
Frequently Asked Questions (FAQs): Synergizing Omic and Symptom Science (R15) (PA 13-265)
What is the Synergizing Omic and Symptom Science (R15) opportunity (PA 13-265)?
PA 13-265 is an NIH grant announcement designed to support research that deliberately links molecular and biological processes ("omics" and related measures) with what patients experience and report, such as symptoms, functional status, and health-related quality of life.
What is the main purpose of this funding opportunity?
The main purpose is to move beyond studying biology or symptoms in isolation by integrating biological/omic data with patient-reported outcomes. The goal is to better understand why symptoms occur, how they vary between people, how they cluster, how they change over time, and how symptom patterns relate to underlying biological mechanisms.
What kinds of data does NIH expect projects to integrate?
The announcement emphasizes combining omics-style data (for example, genetic, genomic, proteomic, metabolomic, inflammatory, or other biological process measurements) with patient-reported outcomes such as symptoms, functional status, and health-related quality of life.
What does "omics" mean in the context of this opportunity?
In this context, "omics" refers broadly to high-dimensional or system-level biological measurements, including (as examples provided) genetic, genomic, proteomic, metabolomic, inflammatory, or other biological process measurements used to reflect what is happening at the molecular and biological level.
What are patient-reported outcomes (PROs) in this announcement?
Patient-reported outcomes here include what patients report and experience directly, such as symptoms, functional status, and health-related quality of life.
What is meant by "symptom science" in this program description?
Based on the announcement summary, symptom science refers to research focused on understanding symptoms and symptom patterns (including why symptoms occur, differ among individuals, cluster, or change over time), especially when paired with biological evidence to develop more mechanistic and integrative explanations.
What NIH grant mechanism is used for PA 13-265?
This opportunity uses the NIH R15 mechanism, also known as the Academic Research Enhancement Award (AREA).
What is the intent of the R15 (AREA) mechanism?
R15 grants are generally intended to strengthen the research environment in educational institutions and to support meritorious research while exposing students to research experiences.
What is the funding instrument type and activity category?
The funding instrument type is a grant. The activity category is listed under education and health.
What CFDA number is associated with this opportunity and what does it indicate?
The CFDA number listed is 93.361 (Nursing Research). This indicates alignment with health research priorities that include, but are not limited to, nursing and symptom science.
What is the award ceiling for this opportunity?
The award ceiling is listed as $300,000.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of receiving the award.
When was this opportunity posted and when did it close?
It was posted on July 9, 2013. The original and final closing date was September 7, 2016.
Is PA 13-265 currently open for applications?
No. The opportunity was archived on October 8, 2016, and the final closing date was September 7, 2016, so this specific announcement is no longer open.
Why might this archived announcement still be useful?
Even though it is no longer open, the summary is useful for understanding the type of integrative research NIH was seeking under this program and for identifying similar current opportunities with comparable aims.
Who is eligible to apply?
Eligibility is centered on institutions of higher education. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are minority-serving institutions specifically mentioned as eligible applicants?
Yes. The announcement calls out Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs) as additional eligible applicant types.
Are foreign institutions eligible to apply directly?
No. Foreign institutions (non-U.S. entities) are explicitly not eligible to apply.
Are non-domestic components of U.S. organizations eligible?
No. The announcement states that non-domestic components of U.S. organizations are also not eligible.
Are any foreign activities allowed under this opportunity?
Yes. The summary states that foreign components, as defined by the NIH Grants Policy Statement, are allowed. This typically means a U.S. applicant organization can include well-justified project activities conducted in a foreign setting when necessary for the project and consistent with NIH policy requirements.
What agency sponsors this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What does the announcement suggest about what strong proposals would look like?
The announcement emphasizes bringing together diverse data types. This signals that strong proposals would typically include thoughtful plans for collecting, harmonizing, and analyzing both biological measures and patient-reported measures, rather than treating one as an optional add-on.
What types of research teams or expertise are implied by the announcement summary?
The summary indicates that responsive projects typically emphasize multidisciplinary collaboration, such as combining clinical symptom expertise, biostatistics, and bioinformatics, along with rigorous patient-reported outcome measurement, careful selection of biological markers or omics platforms, and analysis strategies that can link multilevel biological signals to symptom variability and quality-of-life impacts.
What kinds of research questions does the program description highlight?
The description highlights questions about why symptoms occur, why they vary between people, how symptoms cluster together, how they change over time, and how these symptom patterns relate to underlying biological mechanisms measured through omics or other biological processes.
Does the announcement require a specific type of biological platform or marker set?
The provided summary lists examples of biological measures (genetic, genomic, proteomic, metabolomic, inflammatory, or other biological process measurements) but does not state that only one specific platform is required.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants site, with an Additional Information link pointing to the archived Funding Opportunity Announcement (FOA) page.
Who is the contact for technical issues related to accessing the announcement?
For technical issues accessing the announcement or for linking problems, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Is the listed contact a scientific or programmatic point of contact?
No. The summary describes this contact as a support contact for technical issues, not a scientific or programmatic contact.
Browse more opportunities from the same category: Education Health
Next opportunity: Synergizing Omic and Symptom Science (R01)
Previous opportunity: NEI Center Core Grants for Vision Research (P30)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 265
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 265) also looked into and applied for these:
| Funding Opportunity |
|---|
| Synergizing Omic and Symptom Science (R01) Apply for PA 13 264 Funding Number: PA 13 264 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Use Disorders (U01) Apply for PAR 13 270 Funding Number: PAR 13 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $5,000,000 |
| Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (R01) Apply for RFA DA 14 014 Funding Number: RFA DA 14 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (Admin Supp) Apply for PA 13 275 Funding Number: PA 13 275 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Abuse Resistant and Abuse Deterrent Formulations and Devices to Avoid the Abuse, Misuse and Diversion of Prescription Opioids by Patients (SBIR)(R43/R44) Apply for RFA DA 14 013 Funding Number: RFA DA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PAR 13 282 Funding Number: PAR 13 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| NLM Career Development Award in Biomedical Informatics (K01) Apply for PAR 13 284 Funding Number: PAR 13 284 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Evidence Effective Palliative/End of Life Care Interventions (R01) Apply for PAR 13 289 Funding Number: PAR 13 289 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Express Research Grants in Biomedical Informatics (R01) Apply for PAR 13 300 Funding Number: PAR 13 300 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 13 294 Funding Number: PAR 13 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 297 Funding Number: PAR 13 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 298 Funding Number: PAR 13 298 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 317 Funding Number: PAR 13 317 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 318 Funding Number: PAR 13 318 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| National Cancer Institute Program Project Applications (P01) Apply for PAR 13 321 Funding Number: PAR 13 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Increased Knowledge and Innovative Strategies to Reduce HIV IncidenceiKnow Projects (R01) Apply for PAR 13 323 Funding Number: PAR 13 323 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR R43/44) Apply for PAR 13 327 Funding Number: PAR 13 327 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 13 330 Funding Number: PAR 13 330 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Health Promotion Among Racial and Ethnic Minority Males (R21) Apply for PA 13 331 Funding Number: PA 13 331 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) Apply for PAR 13 334 Funding Number: PAR 13 334 Agency: National Institutes of Health Category: Education Health Funding Amount: $3,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 265", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.